Victor F. Zevallos

Dr. Victor F. Zevallos

Department of Applied Sciences, D223 Ellison Building, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK. NE1 8ST
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
VZVictor F. Zevallos
Victor F. Zevallos
VRVerena Raker
Verena Raker
STStefan Tenzer
Stefan Tenzer
CJCarolina Jimenez-Calvente
Carolina Jimenez-Calvente
MAMuhammad Ashfaq-Khan
Muhammad Ashfaq-Khan
DSDetlef Schuppan
Detlef Schuppan

1 June 2019 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ACAlberto Caminero
Alberto Caminero
JMJustin L. McCarville
Justin L. McCarville
VZVictor F. Zevallos
Victor F. Zevallos
MPMarc Pigrau
Marc Pigrau
XYXuechen B. Yu
Xuechen B. Yu
EVElena F. Verdu
Elena F. Verdu

10 June 2015 in Hepatology
Verified
Journal Article
Open access
PDF file
CCCarolina Jiménez Calvente
Carolina Jiménez Calvente
ASAlfica Sehgal
Alfica Sehgal
YPYury V. Popov
Yury V. Popov
YKYong Ook Kim
Yong Ook Kim
VZVictor F. Zevallos
Victor F. Zevallos
DSDetlef Schuppan
Detlef Schuppan
Fibrosis accompanies the wound‐healing response to chronic liver injury and is characterized by excessive hepatic collagen accumulation dominated by collagen type I. Fibrosis often progresses to cirrhosis. Here we presentin vivoevidence of an up to 90% suppression of procollagen α1(I) expression, a reduction of septa formation, and a 40%‐60% decrease of collagen deposition in mice with progressive and advanced liver fibrosis that received cationic lipid nanoparticles loaded with small interfering RNA to the procollagen α1(I) gene. After intravenous injection, up to 90% of lipid nanoparticles loaded with small interfering RNA to the procollagen α1(I) gene were retained in the liver of fibrotic mice and accumulated in nonparenchymal more than parenchymal cells for prolonged periods, significantly ameliorating progression and accelerating regression of fibrosis.Conclusion: Our lipid nanoparticles loaded with small interfering RNA to the procollagen α1(I) gene specifically reduce total hepatic collagen content without detectable side effects, potentially qualifying as a therapy for fibrotic liver diseases. (Hepatology2015;62:1285‐1297)

1 February 2014 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
VZVictor F. Zevallos
Victor F. Zevallos
IHIrene L Herencia
Irene L Herencia
FCFu Chang
Fu Chang
SDSuzanne Donnelly
Suzanne Donnelly
JEJulia H Ellis
Julia H Ellis
PCPaul J Ciclitira
Paul J Ciclitira
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)

16 July 2020 in Foods
Verified
Journal Article
Open access
PDF file
XHXin Huang
Xin Huang
DSDetlef Schuppan
Detlef Schuppan
LTLuis Eutimio Rojas Tovar
Luis Eutimio Rojas Tovar
VZVictor F. Zevallos
Victor F. Zevallos
JLJussi Loponen
Jussi Loponen
Michael GanzleMichael Ganzle
Michael Ganzle
The ingestion of gluten-containing foods can cause wheat-related disorders in up to 15% of wheat consuming populations. Besides the role of gluten, α-amylase/trypsin inhibitors (ATI) have recently been identified as inducers of an innate immune response via toll-like receptor 4 in celiac disease and non-celiac wheat sensitivity. ATI are involved in plant self-defense against insects and possibly in grain development. Notably, they are largely resistant to gastrointestinal proteases and heat, and their inflammatory activity affects not only the intestine, but also peripheral organs. The aim of this study was to understand the changes of ATI throughout the sourdough and yeast-fermented bread-making processes. ATI tetramers were isolated, fluorescein-labelled, and added to a mini-dough bread-making system. When the pH decreased below 4.0 in sourdough fermentation, the ATI tetramers were degraded due to the activation of aspartic proteases, whilst in yeast fermentation, ATI tetramers remained intact. The amylase inhibitory activity after sourdough fermentation decreased significantly, while the concentration of free thiol groups increased. The glutathione reductase activity of Fructilactobacillus sanfranciscensis did not contribute to the reduction of ATI tetramers. Compared to the unfermented wheat, sourdough fermentation was able to decrease the release of pro-inflammatory cytokines monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor alpha (TNF-α) in quantitative ATI extracts added to the human monocytic cell line THP-1. The current data suggest that sourdough fermentation can degrade ATI structure and bioactivity, and point to strategies to improve product development for wheat sensitivity patients.

1 January 2019 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
IBIris Bellinghausen
Iris Bellinghausen
BWBenno Weigmann
Benno Weigmann
VZVictor F. Zevallos
Victor F. Zevallos
JMJoachim Maxeiner
Joachim Maxeiner
SRSonja Reißig
Sonja Reißig
JSJoachim Saloga
Joachim Saloga